Weekly Recap: Novartis $30B market loss and CEO sees midterm sales growth

Novartis AG (USD) (NYSE:NVS) plunged about $30 billion in market value after disappointing trial results, prompting a major shareholder to slam its M&A strategy even as the CEO projects midterm sales growth from upcoming launches and may extend 5%—6% guidance to 2031.Previous Week RecapThis is an A…